My Account
Log in Registration
All
Cart
Highlights
Fiction Books
Non-Fiction Books
Children's Books
Rare Books
Music
DVD & Blu-Ray
Video Games
Category
Wishlists
Cart
All
Free Shipping in the UK
Trustpilot
Proud to be B-Corp

From Breakthrough to Blockbuster Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)

From Breakthrough to Blockbuster By Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)

From Breakthrough to Blockbuster by Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)

Reviews:
£26.69
Condition - New
Only 4 left
New

Summary

From Breakthrough to Blockbuster: The Business of Biotechnology tells the astonishing story of how the biotech industry grew to thousands of small companies around the world, competing with the major pharmaceutical companies that had dominated for a century, and how academic research, venture capital, and contract research organizations worked together to support them.

From Breakthrough to Blockbuster Summary

From Breakthrough to Blockbuster: The Business of Biotechnology by Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)

Financial Times Business Top Title March 2022 How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries? Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

From Breakthrough to Blockbuster Reviews

Written with authority * Financial Times *
A fascinating guide to the complex business of biotechnology, with deep insights into the key factors, players, interactions and behaviors that have shaped the success of this industry. Suitable as a primer for those with no knowledge of the field, or as a refresher for the cognoscenti. Trigger warning: contains material that may distress pharma management * Sir Gregory Winter FRS, Trinity College, Cambridge University, recipient of 2018 Nobel Prize in Chemistry *
A must read for all biotechnology leaders, this is a state-of-the-art analysis of the industry from two of its most successful entrepreneurs and a top business school professor, bringing rigor and actionable insight. * Dr Richard Mason, CEO of Apollo Therapeutics and former head of Johnson & Johnson's London Innovation Center *
How is it possible that a few thousand small companies, many of them short-lived, can out-compete the mighty pharma majors at their own game? Understanding this puzzle is of fundamental importance for industry leaders and policy makers alike. This marvelous insider analysis is a must-read. * Stefan Scholtes, Dennis Gillings Professor of Health Management, Cambridge University Centre for Health Leadership & Enterprise *
A remarkable synthesis and analysis of the Biotech industry that is a must-read for those trying to develop new life-saving medicines. * Margaret A. Liu, M.D., DSchc, MDhc, FISV, CEO of Pax Therapeutics, and board member, Ipsen, S.A. *
Anyone who wants to understand how to leverage ecosystems for innovation in the face of uncertainty must read this rigorous analysis of how biotech companies, investors, government and big pharma have worked together to achieve some of the biggest scientific and commercial breakthroughs of the last century. * Arnoud De Meyer, Professor Emeritus and former President, Singapore Management University *
A must read for everybody interested in the medical biotech industry, practically relevant and theoretically sound. * Jurgen Mihm, , Professor of Technology and Operations Management at INSEAD *
An outstanding overview of the science and the business of innovative drugs. Students, researchers and policy makers will be immensely benefited from this book. * Mahmud Hassan, Ph.D, Professor and Director, Pharmaceutical Management Program, Rutgers Business School *

About Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)

Donald Drakeman, PhD, was the founding CEO of the US biotech company that pioneered the development of the checkpoint inhibitor cancer treatments recognized in the Nobel Prize for Medicine 2018. These products, YERVOY and OPDIVO, are being used to treat many different forms of cancer. He is a Fellow in Operations and Technology Management at the Cambridge Judge Business School, Distinguished Research Professor in the Program on Constitutional Studies at the University of Notre Dame, and a Venture Partner at Advent Life Sciences. His publications have been cited in numerous patents and by the Supreme Court of the United States. He is a Fellow of the Royal Society of Biology. A graduate of Columbia Law School, he received a PhD from Princeton University. Lisa Drakeman, PhD, was the founding CEO of one of Europe's most successful biotechnology companies. Under her leadership, the company set numerous financing records, including a record setting IPO, and inaugurated research programs leading to the new FDA-approved medicines DARZALEX (multiple myeloma) and KESIMPTA (multiple sclerosis). She is a member of the board of the Medical University of South Carolina Foundation for Research Development. She has received numerous industry honors, including the Sol J. Barer Award for Vision, Innovation, and Leadership. She has been a faculty member at Princeton University and regularly lectures on entrepreneurship at universities in the US and Europe. She received a PhD from Princeton University. Nektarios Oraiopoulos, PhD, is the Director of the MPhil Programme in Strategy, Marketing, & Operations and an Associate Professor of Operations and Technology Management at the Cambridge Judge Business School of the University of Cambridge. His research on innovation and R&D management has appeared in the leading journals of the field. He has won multiple awards and has been invited to make presentations at both academic and industry conferences. In addition to his academic work, he has advised entrepreneurial start-ups and has worked closely on research projects with numerous executives from the biopharmaceutical industry. He holds a Diploma in Electrical and Computer Engineering from the National Technical University of Athens and a PhD in Business Administration from the Georgia Institute of Technology.

Table of Contents

List of Figures and Tables Preface Chapter 1: Following the Map of the Genome Chapter 2: The Molecules Chapter 3: The Costly Drug Development Process Chapter 4: The Companies Chapter 5: Biotech-Pharma Alliances Chapter 6: The Biotech Entrepreneur Chapter 7: The Biotech Industry Track Record Chapter 8: The Future of the Biotech Industry Appendix 1 Appendix 2 Bibliography Index About the Authors

Additional information

NGR9780195084009
9780195084009
0195084004
From Breakthrough to Blockbuster: The Business of Biotechnology by Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)
Donald L. Drakeman (Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, Fellow in Operations and Technology Management, Cambridge Judge Business School, and Distinguished Research Professor, Program on Constitutional Studies, University of Notre Dame)
New
Hardback
Oxford University Press Inc
2022-07-07
240
N/A
Book picture is for illustrative purposes only, actual binding, cover or edition may vary.
This is a new book - be the first to read this copy. With untouched pages and a perfect binding, your brand new copy is ready to be opened for the first time

Customer Reviews - From Breakthrough to Blockbuster